BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics (ANTX)AN2 TherapeuticsCompany update

MENLO PARK, Calif. --(BUSINESS WIRE)--May 7, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in

Open original release

Related news

ANTXAN2 Therapeutics2026-02-17 12:00 EST

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

ANTXAN2 Therapeutics2025-11-06 22:03 EST

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

SPROSpero Therapeutics2024-05-16 16:05 EST

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

SPROSpero Therapeutics2025-03-18 08:00 EST

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

OGENOragenics2026-05-19 12:45 EST

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

OGENOragenics2026-02-02 13:30 EST

Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

BRNSBarinthus Biotherapeutics2025-09-30 12:01 EST

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

SCYXSCYNEXIS2025-11-17 15:15 EST

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

View all latest news

AN2 Therapeutics

AN2 Therapeutics is an infectious-disease company focused on novel anti-infective medicines. Its platform is aimed at serious bacterial and related infectious conditions where new options matter.

Recent company news

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-05-07 20:01 EST

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

ANTXAN2 Therapeutics2026-03-31 11:00 EST

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

Stock data

Close
4.93 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States